Table 1.
An acute febrile patient with a confirmed diagnosis of dengue virus infection was considered as Dengue with warning sign (DWS) or SD-SPL modified from the criteria of 2009 WHO guidelines.
Fig 1.
Of 113 patients enrolled, 63 had laboratory-confirmed dengue infection. One patient hospitalized in shock presentation was excluded. Six SD-SPL and ten DWS, with early stage plasma collected, were included in the current study.
Table 2.
Characteristics of dengue patients.
Fig 2.
Identification of angiotensinogen (AGT) and antithrombin III (AT III) proteins.
Representative precursor ion and MS/MS spectra of reporter ions from peptide ALQDQLVLVAAK and DPTFIPAPIQAK of AGT (A) and from peptide RVWELSK and ATEDEGSEQKIPEATNR of AT III (B). Quantification was derived from the signal intensities of eight iTRAQ reporter ions.
Table 3.
List of differentially expressed plasma proteins of SD-SPL compared with those of DWS (p<0.05).
Table 4.
Biological analysis of identified proteins using PANTHER classification.
Fig 3.
Western-blot analysis validating iTRAQs results for angiotensinogen and antithrombin III.
Representative protein bands in DWS (n = 10) and SD-SPL (n = 6) for AGT (A) and for AT III (C). Quantification of relative protein expression of AGT (B) and AT III (D), based on normalized densitometry to healthy control, *p < 0.05.
Fig 4.
Receiver operating characteristic (ROC) curves comparing antithrombin III and angiotensinogen markers for SD-SPL prediction.
Area under the curve (AUC) for antithrombin III = 0.85, AUC for angiotensinogen = 0.83 and AUC for combination of two markers = 0.87.
Table 5.
Multivariate logistic regression analysis of SD-SPL predictive diagnosis.